In a new study published this week, scientists describe their discovery that: “The combination of CBD and clobazam produced an anticonvulsant effect against hyperthermia‐induced seizures (in mouse) that was greater than that observed with either CBD or clobazam alone.”
GW Pharmaceuticals’ research and development for the therapeutic use of cannabinoids dates back at least two decades.
GW Pharmaceuticals is conducting a clinical trial on the effectiveness of its #CBD drug in treating tremors in #Parkinson’s Disease.
The company said it expects to complete the study in June 2019.
First drug (Epidiolex) containing purified substance derived from marijuana was approved by U.S. FDA: We’ll continue to support rigorous scientific research on potential medical uses of marijuana-derived products,” said FDA Commissioner Scott .Gottlieb
Large clinical trial – King’s College London – seeks to affirm CBD as a treatment for psychosis..
“CBD has emerged as a promising candidate as it displays anti-anxiety and anti-psychotic like properties in animals and humans.”
Drug company earning multi-millions on MS med containing only 2 ingredients – THC and CBD ready to launch epilepsy drug this fall & now racing to develop CBD drugs for schizophrenia, #autism & other hard-to treat diseases.
CBD has beneficial effects in patients with schizophrenia and may represent a new class of treatment for the disorder.
With an FDA nod to GW Pharma, the CBD-based anti-seizure medication Epilodex will be on the market before the end of 2018. First-of-its kind medical trial seizures in children with a rare, life-threatening type of epilepsy.